Changes in Hong Kong stocks | Baiyunshan (00874) fell nearly 6% after the results, R&D expenses increased significantly, and net profit fell 16.7% year-on-year in the first half of the year

The Zhitong Finance App learned that Baiyunshan (00874) fell nearly 6% after the results. As of press release, it had a decrease of 5.64% to HK$14.22, with a turnover of HK$61.626,600.

According to the news, Baiyunshan announced interim results, with operating income of 42,091 billion yuan, a slight increase of 0.6% over the previous year; net profit attributable to shareholders was 2,096 billion yuan, down 16.7% year on year. Part of the reason for the pressure on profits in the first half of the year was due to strategic adjustments. The company's R&D investment increased 20.36% year-on-year in the first half of the year, striving to create a second growth curve through scientific and technological innovation, and exchange short-term pain for long-term core competitiveness.

Financial reports show that in terms of research and development, Baiyunshan focuses on the five major advantage areas of malignant tumors, chronic disease management, respiratory, immune system, and male medication, and has laid out more than 160 research projects, including 11 Class 1 innovative drugs, 2 in phase I clinical phase, 4 in phase II clinical phase, and 1 in the marketing license application stage. Furthermore, Wang Laoji, a subsidiary of Baiyunshan that specializes in natural drinks, continues to accelerate the pace of internationalization.